In this study, we show that malignant plasma cells from patients with either primary (n = 12) or secondary (n = 15) plasma cell leukemia (PCL) do not express CD56 at all, neither in the bone marrow nor the peripheral blood in 81% of cases. On the other hand, multiple myeloma (MM) at diagnosis overexpress it in 63 of 94 (67%) cases (P = 0.0001). In three secondary PCL evaluated serially, CD56 was also lacking at diagnosis showing that CD56 is not downregulated at the end stage of the disease but rather not upregulated in this subset of patients. This last concept is strengthened by the observation that 29% of MM patients lacking CD56 or weakly expressing it at diagnosis present a detectable leukemic phase vs 11% only in CD56
Introduction
It is now clear that NCAM, ie neural cell adhesion molecule, CD56, is mainly involved during normal embryogenesis in the phenomenon of axon growth and guidance. 1 It is a recognition molecule that operates via both homophilic (NCAM to NCAM) and heterophilic binding mechanisms (NCAM to heparan sulfate proteoglycan and various collagens). 1 During embryogenesis, this molecule is downregulated during migrating events but re-expression usually occurs when target organs are reached. 1 This molecule is also expressed by some nonhematopoietic and hematopoietic tumors. 1 Van Camp et al 2 were the first to show that the malignant plasma cells of patients with multiple myeloma (MM) expressed CD56 whereas normal plasma cells did not. We and others have confirmed this observation on a large number of patients. [3] [4] [5] [6] [7] [8] [9] Moreover, in our own previous study performed in patients with MM, we had suspected that CD56 was significantly involved in the homing and circulation of myeloma cells as for normal cells during embryogenesis. 9 To progress on this point we have focused on the expression of this important adhesion molecule on normal and malignant plasma cells, especially those circulating in the peripheral blood or homing in extramedullary sites of MM.
In the current study, we show that the malignant plasma cells of 27 patients with either primary or secondary plasma cell leukemia (PCL) do not express or weakly express CD56 and thus do not upregulate this molecule at their cell surface, in contrast to what is observed in almost 70% of patients with MM. Furthermore, focusing our attention on the one-third of patients with MM who do not express or weakly express CD56 at diagnosis (as PCL), we show that it represents a particular subset of patients. Finally, our current data give some insights on the role of CD56 in MM.
Materials and methods

Patients
The expression of CD56 on plasma cells was investigated in three healthy individuals (bone marrow), two patients undergoing tonsillectomy, 10 reactive plasmocytoses (peripheral blood), 94 consecutive patients with MM at diagnosis, 12 patients with a primary PCL and 15 with a secondary PCL. For these latter patients with either primary or secondary PCL, the phenotype of myeloma cells was determined on bone marrow, peripheral blood or both bone marrow and peripheral blood. The diagnostic criteria for MM were those of the Southwest Oncology Group. 10 Patients with primary PCL had more than 20% of malignant plasma cells (or more than 2000/l) in their peripheral blood. Furthermore, four patients with MM and subsequent extramedullary relapse have been investigated (one ascitis, three pleural effusions). Ten patients with peripheral blood reactive plasmocytosis during the course of either viral infections (n = 8) or B and T cell lymphomas (n = 2) were included. In these patients, peripheral blood plasma cells were processed as myeloma cells.
Monoclonal antibodies
Monoclonal antibodies (mAbs) against the following antigens were used: Apo 2.7, CD19, CD28, CD38, CD56 and CD138 (ie syndecan-1). Apo 2.7-PE, anti-CD19-PE (phycoerythrin), anti-CD28-FITC (fluorescein), anti-CD38-FITC, control IgG1-FITC and control IgG1-PE were obtained from Immunotech (Marseilles, France); anti-CD28-PE and anti-CD56-PE from Becton Dickinson (Heidelberg, Germany); rabbit anti-human kappa light chain-PE antibody from Dako (Glostrup, Denmark); and mouse anti-human lambda light-chain-PE from Caltag Laboratories (San Francisco, CA, USA). B-B 4 , anti-CD138 mAb was a gift from Dr J Wijdenes, Diaclone Research (Besançon, France). CD138 is specific for normal and malignant plasma cells in bone marrow and peripheral blood and recognizes syndecan-1.
11 Purified B-B 4 mAb was biotinylated as previously described.
Phenotypic analysis
For immunofluorescence staining, 5 × 10 5 cells were incubated with different FITC or PE or biotinylated mAbs for 30 min at 4°C in the presence of 20% human AB serum followed by incubation (20 min, 20°C) of streptavidin coupled to Quantum Red (QR) (Sigma, St Louis, MO, USA). Cells were fixed in 1% formaldehyde and analyzed on a FACScalibur flow cytometer with Cell Quest Software (Becton Dickinson). Data acquisition was always performed in two steps: firstly, 10 000 total cells were collected, and secondly, at least 5000 plasma cells (CD138 + ) were acquired with an activated live gate on SSC vs CD138 dot-plot. Apoptotic plasma cells were recognized by low expression of CD138 and Apo 2.7 staining and excluded from analysis. The interest in using CD138 to define plasma cells has been validated by ourselves 8 and recently confirmed by others.
12
CD138 plasma cell identification was controlled by coexpression of CD38 and intracytoplasmic / immunofluorescence, in a three-color assay. 13 The mean fluorescence ratio (MFR) was calculated as follows: mean of specific fluorescence/mean of control fluorescence.
Statistical analyses
The Wilcoxon rank sum test, the 2 test (with Yates correction, if necessary) and the Fisher exact test were used for statistical studies.
Results
CD56 is highly expressed in the majority of patients with MM at diagnosis, in comparison with normal plasma cells
Normal plasma cells from either the bone marrow of healthy individuals and tonsils (n = 5) or the peripheral blood of patients with reactive plasmocytosis (n = 10) do not express CD56 at all. On the other hand, 63 of 94 (67%) cases of MM at diagnosis strongly express CD56 on more than 90% of malignant plasma cells (mean fluorescence ratio, MFR: median value 52, range 4-732). These patients are referred as CD56
+ MM in the current study. In 18 of 94 (19%) cases, CD56 is weakly expressed on a subpopulation of myeloma cells only (median 25%, range 12-81%). Indeed, the level of CD56 expression of these patients is significantly less than that of the former patients: median MFR 22, range 5-113 (P = 0.001). Finally, 13 of 94 patients with MM (14%) do not express CD56 at all (P Ͻ 0.0001 for difference with the nonmalignant states) ( Figure 1 ). These last two categories of patients are referred to as CD56 weak and CD56 − MM, respectively.
The expression of CD56 discriminates MM from PCL CD56 is not expressed in the majority of patients with secondary PCL, either in the bone marrow or in the peripheral blood:
We have investigated bone marrow (n = 13) and peripheral blood (n = 9) samples from 15 secondary PCL. In eight cases, both bone marrow and peripheral blood samples were available for phenotypical analysis in the same patient. CD56 is expressed (but five-fold less than in MM, ie MFR 10) in two cases (13%) and weakly or not expressed at all in the 13 remaining cases (87%) (with more than 90% of myeloma cells being negative) regardless of the origin of the samples (Figure 1) . Thus, secondary PCL have a homogeneous phenotype, ie CD56 −/weak , in both sites (ie peripheral blood and bone marrow). In these patients, to see whether CD56 was downregulated during tumor progression (or not), we had the opportunity to compare the CD56 −/weak phenotype of three of these patients with secondary PCL with that evaluated at diagnosis. Both phenotypes were identical, showing that CD56 was not downregulated during tumoral expansion but rather not expressed in the bone marrow at diagnosis (Figure 2 ). This observation also suggests that secondary PCL emerge preferentially from CD56 −/weak MM.
CD56 is not expressed in the majority of patients with primary PCL, either in the bone marrow or the peripheral blood:
We have investigated bone marrow (n = 6) and peripheral blood (n = 12) samples from 12 primary PCL. In six cases, both bone marrow and peripheral blood samples were available for phenotypic analysis in the same patient. CD56 is weakly expressed (but five-fold less than in MM, ie MFR 9) in three cases (25%) and weakly or not expressed at all in the nine remaining cases (75%). Thus, primary PCL, as secondary PCL have a homogeneous phenotype: CD56 −/weak in both sites (ie peripheral blood and bone marrow).
CD56 is expressed in patients with extra-medullary involvement:
Four patients have been evaluated at the time of extramedullary relapse (one ascitis, three pleural effusions). In these cases, neither bone marrow nor peripheral blood was involved by the malignant process. CD56 is expressed in three of four cases (Figure 1 ).
CD28 but not CD56 discriminates secondary from primary PCL
Because we have previously shown that CD28 is a marker associated with tumoral expansion in MM, 13 we have looked at its expression on this large cohort of patients with PCL. CD28 is detected in 13 of 14 patients with a secondary PCL, more frequently in the peripheral blood (12 of 13 cases, 92%) than in the bone marrow (five of nine cases, 55%) (not significant). In the three previous patients evaluated for putative CD56 downregulation, we have clearly shown that CD28 was upregulated between diagnosis and the occurrence of the secondary leukemic phase (data not shown). Thus, circulating myeloma cells from secondary PCL have a homogeneous phenotype CD56
−/weak and CD28
+
. On the other hand, only 33% of primary PCL express CD28 in the bone marrow or in the peripheral blood (P Ͻ 0.001 for difference with secondary PCL). This percentage of positivity is not different from that of 94 MM cases at diagnosis (28%). Taking together all the data, both primary and secondary PCL have a homogeneous phenotype CD56
−/weak significantly different from that of MM (CD56 + ). However, CD28 clearly discriminates primary PCL (CD28 +/− and identical to MM) from secondary PCL (CD28 + ). In both primary and secondary PCL, CD19 was not expressed on myeloma cells at all (data not shown).
Figure 1
Expression of CD56 in patients with multiple myeloma (MM) at diagnosis, in comparison with normal plasma cells in the bone marrow, plasma cells from peripheral blood reactive plasmacytosis and myeloma cells from either primary or secondary plasma cell leukemia (PCL) and from extramedullary relapse.
Figure 2
Analysis of CD56 expression in a MM patient (a) in bone marrow myeloma cells at diagnosis and (b) in peripheral blood myeloma cells at relapse 3 years later. The CD56 expression in malignant plasma cells has been analyzed in two-color immunofluorescence in combination with CD38FITC at diagnosis and in combination with CD138QR at relapse. The percentage of CD56 + myeloma cells is indicated.
The CD56 −/weak MM subset at diagnosis has particular presenting features
Although the lack of or weak CD56 expression is a hallmark of patients with PCL, either primary or secondary cases, 31/94 (33%) previously untreated patients with MM do not or weakly express this antigen at diagnosis. Considering the clear association between the lack of CD56 and a leukemic phase, we looked for the presence of a minimal leukemic phase in patients with CD56
−/weak MM at diagnosis. The presence of circulating malignant plasma cells was evaluated on routine peripheral blood smears. No effort was made to enrich samples for plasma cells. Malignant plasma cells (Ͻ2000/l) in the peripheral blood were observed in 9/31 (29%) CD56 −/weak MM at diagnosis but in only 7/63 (11%) CD56
+ MM (P = 0.06). Thus, combining MM at diagnosis and primary PCL, 40% of CD56 −/weak malignant plasma cell disorders presented a leukemic phase (with more or less 2000 malignant plasma cells/l) vs only 15% of CD56 + MM disorders (P Ͻ 0.008) (Table) .
In the literature, a hallmark of patients with primary PCL is their low osteolytic potential since a majority of them have no lytic bone lesion on bone radiography at presentation. 14 This is also the case in our current pool of 12 patients (data not shown). More recently, this concept was strengthened by the observation that patients with MM and circulating malignant plasma cells (but not fulfilling the diagnostic criteria of primary PCL) also presented fewer lytic bone lesions. 15 Thus, we have evaluated the osteolytic potential, ie number of major osteolytic lesions on radiography of CD56 −/weak MM in comparison with that of CD56 + MM at diagnosis. Considering the presence of lytic bone lesion on radiography, 56% of CD56 −/weak MM, as primary PCL, had no bone lesion at presentation (vs only 20% in CD56 + MM, P = 0.012) ( Table 1) . By looking more carefully at the two MM subsets, we show that the expression of CD138 is significantly lower in CD56 −/weak MM (MFR, median value 340, range 160-542) than in CD56 + MM (649, 34-3278, P Ͻ 0.05). In the current work, we have shown that CD28 was upregulated in 27 of 94 cases (28%) at diagnosis, thus, less frequently than CD56: 63/94 (67%, P = 0.0001 for difference with CD56 expression). We compared the expression of CD28 in CD56 + and CD56 −/weak MM at diagnosis. CD28 is expressed in 50% of CD56 −/weak MM but in only 20% of CD56 + MM (P = 0.007). More than 1% of malignant plasma cells on blood smears. In P-PCL, the percentage is у20% in all the cases. b Defined as the percentage of patients with lytic bone lesions on bone radiography. P-PCL, primary plasma cell leukemia as reference population of patients.
Discussion
Our current study is the first to evaluate the expression of CD56 on normal and malignant plasma cells, especially those circulating in the peripheral blood or homing in extramedullary sites of MM. Firstly, we have shown that reactive plasmocytoses do not express CD56. These states are characterized by the expansion of highly proliferative polyclonal plasma cells in the bone marrow and peripheral blood. 16 Thus, these plasma cells are not different in terms of CD56 expression from normal plasma cells homed inside the bone marrow. Indeed, we have confirmed here that these latter plasma cells do not express CD56 as initially described. 2 Of note, the precursor of these differentiated plasma cells normally migrate from germinal centers to the bone marrow through the peripheral blood in the form of migrating plasmablasts which do not express CD56 (Jego et al, submitted) . These cells clearly do not upregulate CD56 once in the bone marrow. Secondly, we have shown that 70% of myeloma tumors expanding within the bone marrow expressed CD56 brightly and that 75% of extra-medullary tumors also expressed CD56. On the other hand, myeloma cells from PCL, either primary or secondary, generally do not express CD56 either in the peripheral blood or in the bone marrow. From a practical point of view, CD56 expression clearly discriminates PCL from MM and extra-medullary tumors. The number of extra-medullary tumors is too small to draw any conclusion. It will be of major interest to study CD56 expression at different sites (bone marrow, blood, extra-medullary tumor) in the same patient to progress on this point. The fact that CD56 was weakly or not expressed in three cases of secondary PCL at diagnosis in the bone marrow suggests that CD56 is not downregulated in PCL but rather that myeloma cells in cases of PCL have not upregulated this molecule either in the bone marrow or the peripheral blood. Thus, these cells retain a normal phenotype and the capacity to recirculate through the peripheral blood while accumulating within the bone marrow. Of note, their interactions with bone are clearly less strong. On the other hand, malignant plasma cells which upregulate CD56 in the bone marrow, develop more aggressive interactions with bone and lose their capacity to recirculate at least massively (in the form of overt PCL). The biology of NCAM could explain these observations. Homotypic interactions between myeloma cells through NCAM could facilitate the spatial organisation of CD56 bright myeloma cells into nodules and this mode of tumoral organization could be more aggressive for bone trabeculae. In this context, we have shown that NCAM was involved in the interactions between myeloma cells and bone cells. 17 Conversely, interactions between myeloma cells themselves and between myeloma cells and bone cells could be weaker in CD56 −/weak MM favoring leukemic expansion. This concept is also strengthened by the demonstration that CD56
− cells secrete more MMP-9 than CD56 + cells 18 and thus could degrade basal membrane and circulate at distance more easily. This is in agreement with the recent demonstration that NCAM transfection in tumor cells made them less aggressive in terms of expansion in vivo. 19 Of note, NCAM has been shown in some instances to function via transmembrane signaling. 20 On the other hand, the mechanisms of the upregulation of this molecule in the majority of patients with MM remain unknown. 21 It is noteworthy that we were able to isolate a subset of MM characterized by a lack of or a weak expression of CD56, a weak expression of CD138, a less aggressive bone disease and a tendency to develop primary or secondary leukemic phase more frequently. Thus, this subset more resembles PCL than
CD56
+ MM. Our data disagree with those of Mathew et al, 22 who were unable to characterize such a subset. However, this could be explained by the fact that their criteria of CD56 positivity differed from our own criteria. Clearly, their CD56 − MM patients (45% of their patients) did not overlap our CD56 − population of patients. On the other hand, our data are in complete agreement with those of Rawstron et al, 12 showing a weaker expression of CD56 on circulating myeloma cells in MM lacking overt PCL. A last point deserves some comment. We have shown in the current work that this MM subset expressing no CD56 and less CD138, preferentially overexpressed another antigen CD28. We have also shown that CD28 was able to discriminate secondary from primary PCL. We have been the first to show that CD28, a T cell antigen involved in T cell activation, was curiously expressed on malignant plasma cells from patients with MM. 8 More recently, we have found that this antigen was clearly upregulated during tumoral expansion. 13 In the current work, we show that CD28 is expressed earlier (ie as soon as the diagnosis) more frequently in CD56
− MM than in CD56 + MM. Furthermore, we show that this antigen is strongly upregulated in cases of secondary PCL, allowing a significant discrimination with primary PCL. Of note, this antigen like CD56 is not expressed on normal bone marrow plasma cells and on peripheral blood reactive plasmocytoses. Thus, in CD56 − malignant plasma cell disorders, CD28 could be a surrogate of CD56 and could favor interactions between the myeloma cells themselves. Indeed, we have found that CD28 was expressed with its ligand CD86 (but not CD80) on myeloma cells, 13 and it has been documented that CD28 mediated adhesion of T cells with B cells by interacting with its ligand. 23 Of note, although we and others were unable to define a function of CD28 on myeloma cells, this molecule is clearly functional. 13, 24 Finally, the mechanisms involved in the upregulation of CD28, as those involved in that of CD56, remain unknown.
In conclusion, we have shown that whereas a majority of MM upregulate CD56 at diagnosis, a majority of PCL do not. Thus, CD56 discriminates PCL from MM. This concept is strengthened by the observation that we could delineate a CD56 −/weak MM subset mimicking PCL, ie frequent leukemic phase at diagnosis or development of secondary PCL associated with a low osteolytic potential. Furthermore, we have shown that CD28, another antigen which is also upregulated in MM in comparison with normal plasma cells appears to be a surrogate of CD56. Although this antigen is associated with tumoral expansion in all the patients with MM, it is expressed earlier in CD56 − MM. Finally, its strong upregulation in secondary PCL (whereas it was not expressed on peripheral blood reactive plasmocytoses or on a minor subset only), makes it useful to discriminate primary from secondary PCL. Further investigations will be necessary to understand (1) the mechanisms of both CD56 and CD28 upregulation on myeloma cells in contrast to normal plasma cells, (2) the role of these molecules in MM and (3) the balance between CD56 and CD28 expressions.
